AVXL Company Profile and Key Details
NASDAQ : AVXL
Anavex Life Sciences
$4.53
0.1+2.26%
At Close 4:00 PM61.67
BESG ScoreESG Rating
Price Chart
Stock Price Today
Anavex Life Sciences Corp. (AVXL) stock surged +2.26%, trading at $4.53 on NASDAQ, up from the previous close of $4.43. The stock opened at $4.31, fluctuating between $4.30 and $4.66 in the recent session.
Stock Snapshot
4.43
Prev. Close
419.8M
Market Cap
4.301
Day Low
-9.85
P/E Ratio
-0.46
EPS (TTM)
-0.36
Cash Flow per Share
4.31
Open
92.67M
Number of Shares
4.66
Day High
98.18%
Free Float in %
1.65
Book Value
918.67K
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Mar 02, 2026 | 4.31 | 4.66 | 4.30 | 4.53 | 922.65K |
| Feb 27, 2026 | 4.40 | 4.46 | 4.28 | 4.43 | 2.29M |
| Feb 26, 2026 | 4.43 | 4.49 | 4.24 | 4.46 | 858.85K |
| Feb 25, 2026 | 4.40 | 4.70 | 4.36 | 4.40 | 1.19M |
| Feb 24, 2026 | 4.17 | 4.43 | 4.15 | 4.36 | 1.01M |
| Feb 23, 2026 | 4.09 | 4.24 | 4.07 | 4.16 | 573.79K |
| Feb 20, 2026 | 4.15 | 4.18 | 4.07 | 4.12 | 800.16K |
| Feb 19, 2026 | 4.13 | 4.14 | 4.00 | 4.12 | 735.33K |
| Feb 18, 2026 | 4.03 | 4.16 | 4.00 | 4.04 | 932.69K |
| Feb 17, 2026 | 3.97 | 4.09 | 3.89 | 4.04 | 886.2K |
| Feb 13, 2026 | 3.98 | 4.18 | 3.91 | 3.93 | 1.08M |
| Feb 12, 2026 | 3.90 | 4.00 | 3.78 | 3.92 | 1.34M |
| Feb 11, 2026 | 3.97 | 4.04 | 3.74 | 3.88 | 1.4M |
| Feb 10, 2026 | 4.34 | 4.35 | 3.95 | 3.96 | 1.67M |
| Feb 09, 2026 | 4.20 | 4.54 | 4.07 | 4.35 | 1.8M |
| Feb 06, 2026 | 3.86 | 4.26 | 3.82 | 4.10 | 1.68M |
| Feb 05, 2026 | 4.14 | 4.19 | 3.81 | 3.81 | 1.43M |
| Feb 04, 2026 | 4.44 | 4.44 | 4.10 | 4.13 | 2.62M |
| Feb 03, 2026 | 4.50 | 4.65 | 4.33 | 4.39 | 1.26M |
| Feb 02, 2026 | 4.62 | 4.70 | 4.49 | 4.52 | 1.39M |
Contact Details
About Company
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Company Information
| Employees | 42 |
| Beta | 1.07 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | September |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
REGN
9.14+1.17%
Regeneron Pharmaceuticals, Inc.$790.81ARGX-10.16-1.32%
argenx SE$756.76UTHR9.92+1.97%
United Therapeutics Corporation$513.82VRTX-10.8-2.17%
Vertex Pharmaceuticals Incorporated$486.03MDGL3.62+0.84%
Madrigal Pharmaceuticals, Inc.$435.62PRAX-6.16-1.83%
Praxis Precision Medicines, Inc.$330.59KRTX0.09+0.03%
Karuna Therapeutics, Inc.$329.83ALNY-7.85-2.36%
Alnylam Pharmaceuticals, Inc.$325.07KRYS-16.83-6.11%
Krystal Biotech, Inc.$258.81ASND8.59+3.68%
Ascendis Pharma A/S$242.09Company Overview
Anavex Life Sciences Corp. (NASDAQ:AVXL) closed at $4.53 USD, gaining $0.10 (2.26%) from the previous close of $4.43. The stock is currently mid-range between its 52-week high and low $2.86 and $13.99. With a market capitalization of about $419.80 million, Anavex Life Sciences Corp. is classified as a small-cap and shows market-like volatility (beta ~1.07). Key stats such as the average daily volume over the past year has been around 1.77 million shares, volume is running light vs its 52-week average. Headquartered in New York City, NY, Anavex Life Sciences Corp. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Christopher U. Missling, the company employs approximately 42 people and listed since August 02, 2006. Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases.
Technical Performance
AVXL has shown mixed momentum, gaining 17.25% over the past week and -43.99% over the past quarter, though year-to-date performance is up 41.29%. Short-term trend indicators are bullishly aligned (SMA20 5.81%, SMA50 4.44%, SMA200 -40.2%). The stock’s 14-day RSI is 55.14 (neutral), while the ATR of 0.27 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -68.12% below its high and over 55.94% above its low. Average 10-day trading volume of 1.09 million shares is below the 3-month average of 1.75 million, indicating normal recent market interest.
Dividend & Fair Value
Anavex Life Sciences Corp. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.20. This means the shares are trading above this model’s fair value.
Earnings & Analyst Outlook
Anavex Life Sciences Corp. generated EPS of -$0.46 over the past year. Five-year average earnings growth is -3.79%. The latest quarter delivered EPS of -$0.11. The next quarter is forecast at -$0.07. Next year's EPS is expected at $48.28. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 23 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $46.00 to $20.00. The high target offers 915.45% upside. The low target suggests 341.5% downside. The mean target is $34.87. This offers 669.76% upside. Anavex Life Sciences Corp. earnings surprise history is frequent misses against expectations. The quarter that ended November 25, 2025, missed forecasts by -15.38%. The prior quarter beat by 23.08%. Over the last six quarters, Apple has recorded several small beats. These include -6.67% in August 06, 2024.
Shareholding & Insider Activity
Anavex Life Sciences Corp. has 92.67 million shares outstanding. The public float is 89.78 million shares, elevated short interest at 23.06% of float. This equals 20.53 million shares. The short ratio is 14.19 days. Institutional investors hold 38.31% of the float. Insiders own 3.23%. Skarpelos Athanasios holds 1.31 million shares, MISSLING CHRISTOPHER U has 1.25 million shares and Lalach Harvey has 550.00 thousand shares.
Frequently Asked Questions
What is the current Anavex Life Sciences Corp. (AVXL) stock price?
Anavex Life Sciences Corp. (NASDAQ: AVXL) stock price is $4.53 in the last trading session. During the trading session, AVXL stock reached the peak price of $4.66 while $4.30 was the lowest point it dropped to. The percentage change in AVXL stock occurred in the recent session was 2.26% while the dollar amount for the price change in AVXL stock was $0.10.
AVXL's industry and sector of operation?
The NASDAQ listed AVXL is part of Biotechnology industry that operates in the broader Healthcare sector. Anavex Life Sciences Corp. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of AVXL?
Dr. Edward R Hammond M.D., M.P.H., Ph.D.
Chief Medical Officer
Dr. Emmanuel O. Fadiran RPh, Ph.D.
Senior Vice President of Regulatory Affairs
Ms. Sandra Boenisch CPA, CPA, CGA
Principal Financial Officer & Treasurer
Dr. Walter E. Kaufmann M.D.
Chief Scientific Officer
Clint Tomlinson
Vice President of Corporation
Mr. Stephan Toutain
Chief Operating Officer
Dr. Adebayo Laniyonu Ph.D.
Senior Vice President of Nonclinical Devel.
Dr. Christopher U. Missling M.B.A., M.S., Ph.D.
Chairman, Pres, Chief Executive Officer & Sec.
Dr. Kun Jin Ph.D.
Head of Biostatistics
Chief Medical Officer
Dr. Emmanuel O. Fadiran RPh, Ph.D.
Senior Vice President of Regulatory Affairs
Ms. Sandra Boenisch CPA, CPA, CGA
Principal Financial Officer & Treasurer
Dr. Walter E. Kaufmann M.D.
Chief Scientific Officer
Clint Tomlinson
Vice President of Corporation
Mr. Stephan Toutain
Chief Operating Officer
Dr. Adebayo Laniyonu Ph.D.
Senior Vice President of Nonclinical Devel.
Dr. Christopher U. Missling M.B.A., M.S., Ph.D.
Chairman, Pres, Chief Executive Officer & Sec.
Dr. Kun Jin Ph.D.
Head of Biostatistics
How AVXL did perform over past 52-week?
AVXL's closing price is 58.39% higher than its 52-week low of $2.86 where as its distance from 52-week high of $13.99 is -67.62%.
How many employees does AVXL have?
Number of AVXL employees currently stands at 42.
Link for AVXL official website?
Official Website of AVXL is: https://www.anavex.com
How do I contact AVXL?
AVXL could be contacted at phone 844 689 3939 and can also be accessed through its website. AVXL operates from 51 West 52nd Street, New York City, NY 10019, United States.
How many shares of AVXL are traded daily?
AVXL stock volume for the day was 918.67K shares. The average number of AVXL shares traded daily for last 3 months was 1.77M.
What is the market cap of AVXL currently?
The market value of AVXL currently stands at $419.80M with its latest stock price at $4.53 and 92.67M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep